Summary Tumour localisation of anti-tumour antibodies varies greatly between patients. Factors which may be responsible for this have been investigated in 56 patients with colorectal carcinoma with a view to improving radioimmunotherapy. Thirty-seven to seventy-four MBq of 1254-labelled mouse monoclonal antibody to CEA, was given intravenously and tumour resected 70-480 h later. Percentage injected activity kg-' (% inj.act kg-') in tumour, was inversely correlated with the time interval between injection and operation (P = 0.004). To assess the influence of other parameters on localisation, patients were divided into two time groups according to time interval between injection and operation, 70-120 h (n = 33) and 144-480 h (n = 23). In neither group was there a significant correlation of % inj.act kg-' with time. The % inj.act kg-' in tumour showed a significant correlation with that in the blood for both groups (P = 0.005 and P = 0.01). There was no significant correlation for either time group between % inj.act kg- ' (Begent et al., 1985; Martin et al., 1988; Begent, 1990) . There is great variability in uptake of antibody in individual tumours in patients and the factors influencing this are poorly understood. Distribution of injected antibodies within tumours is not uniform (Griffith et al., 1988; Pedley et al., 1990 
Localisation of intravenously administered anti-tumour antibodies in tumours is used clinically in immunoscintigraphy (IS), radioimmunoguided surgery (RIGS) and anitbody targeted therapy of cancer (Begent et al., 1985; Martin et al., 1988; Begent, 1990) . There is great variability in uptake of antibody in individual tumours in patients and the factors influencing this are poorly understood. Distribution of injected antibodies within tumours is not uniform (Griffith et al., 1988; Pedley et al., 1990) . The causes of heterogeneity of intratumour distribution of antibody have been addressed by Cobb, 1989 and Jain and Baxter, 1988 and the consequences of nonuniformity of antibody binding on tumour dose in radioimmunotherapy are discussed by Humm and Cobb, 1990 . Most autoradiographic studies of the distribution of antibody at the microscopic level have been confined to human tumour xenograft model systems in nude mice (Pedley et al., 1990; Sampsel et al., 1990) . In patients, tumour and normal tissues from resected specimens collected following radioimmunoguided surgery with '25I-labelled antibody (Blair et al., 1990) , allows the microdistribution of antibody to be investigated. A number of factors may putatively influence antibody localisation, including antigen heterogeneity, tumour vascularisation and rate of clearance of antibody from the circulation.
This paper attempts to clarify how factors affecting biodistribution of antibody may be important in modifying existing agents or designing new ones for antibody targeted therapy, IS and RIGS. The preoperative administration of radiolabelled antibody for use with RIGS (Blair et al., 1990; Tuttle et al., 1988) provides an opportunity to obtain tissue samples from patients receiving antibody which are suitable for studying the relevant parameters. Autoradiography, combined with immunohistochemical demonstration of CEA and vascular endothelium, shows the relationship of localised antibody to the target antigen and tumour vasculature. Information about the extravasation, penetration, passage and retention of antibody within tumours and factors affecting localisation is essential if new or modified agents are to be designed for efficient antibody directed therapy of cancer.
Patients and methods
Fifty-six patients with colorectal carcinoma gave informed consent to enter the trial. Antibody uptake in thyroid was blocked by administration of potassium iodide and potassium perchlorate. Patients were tested for skin allergy as previously described (Begent et al., 1986) . 0.4 mg of IgGI mouse monoclonal antibody (A5B7) to CEA (Harwood et al., 1986) (Pedley et al., 1987) . Adjacent pieces of tissue were fixed in 10% formalin and processed for routine histology.
Immunohistochemistry for CEA antigen and tumour vessels Four micron sections of formalin-fixed paraffin processed tumour tissue were incubated with two mouse monoclonal antibodies to different epitopes on CEA, F3E3 and A5B7 (Harwood et al., 1986) in an avidin biotin peroxidase technique (Southall et al., 1990 
Autoradiography
Autoradiographic studies were performed in 12 cases in which sufficient radioactive counts were obtained in tumour (in excess of 100,000 counts per minute gram-'). The technique was as previously described (Pedley et al., 1990) . Before covering with autoradiographic film, serial sections of tumour and normal tissues were immunohistochemically stained with an antibody to CEA and with QBend/10 as previously described in the manuscript. Control sections, incubated with biotinylated anti-mouse antibody and avidin biotin peroxidase alone, were always negative. Sections were counterstained after development of the autoradiographs with haematoxylin only.
Statistical analysis
Correlations of the per cent injected activity in tumour and tumour to blood ratios, with blood levels of radioactivity, serum CEA, tumour CEA, vascularity and the time interval between injection and operation were investigated. Correlations of parameters with numerical values were performed using the non parametric Spearman Rank Correlation Test. Correlations of per cent injected activity in tumour with site and the pushing or infiltrative nature of the tumour were performed using the Mann-Whitney U test.
Results
Tumour characteristics and antibody localisation The histological and immunohistochemical (distribution of CEA) characteristics of the tumours, the % inj.act kg-' in tumour, tumour to blood ratios and time interval between injection and operation are shown in Table I . The wide range of % inj.act kg-' in tumour (0.342-10.55) is illustrated.
Most of the tumours were moderately differentiated. The amount of differentiation did not influence tumour uptake of radiolabelled antibody. In most patients, immunohistochemistry showed antigen in tumour to be both cytoplasmic and membrane associated with similar intensity of reaction. In those few patients whose tumours showed a differential intensity in reaction between cytoplasm and membrane there seemed to be no association with % inj.act kg-' in tumour or tumour to blood ratios. In 29/56 necrotic areas constituted less than 5% of total area and in 12/56 necrotic areas constituted 10% or more. These tumours were not associated with higher or lower per cent injected activities. Figure 1 shows the distribution of tumour uptake (inj.act kg-') of 125I anti-CEA in the 56 patients. Whilst 40 of the 56 patients had % inj.act kg' of less than 2% they achieved mean tumour to normal bowel ratios of 3.5.
Although patients with more than 2% injected activities in tumour were less frequent they were associated with higher tumour to normal bowel ratios.
Factors affecting % inj.act kg-' in tumour Table II shows the correlations of % inj.act kg-' in tumour with eight factors. The % inj.act kg-' in tumour was positively correlated with % inj.act kg-' in blood and, for the early time group, with tumour to blood ratio. The other factors had no significant effect. Figure 2 shows a significant inverse relationship between % inj.act kg-' in tumour and the time interval between injection and operation in the 56 patients (P = 0.004). Becuase of this relationship of tumour uptake with time in the whole patient group, in order to investigate the influence of other parameters, the patients were divided into two subgroups according to the time interval between injection and operation. These were 70-120 h (n = 33) and 144-480 h (n = 23). In neither group was there a significant dependence upon time (P = 0.48 and P = 0.07).
There was a significant correlation between % inj.act kg-' in tumour and % inj.act kg-' in blood in the 70-120 h (P = 0.005) and the 144-480 h (P = 0.01) groups.
Tumour to blood ratio There was a significant inverse relationship between % inj.act kg-' in blood and the tumour to blood ratio (P = 0.007) in the 70-120 h group. In the 144-480 h group the relationship did not achieve significance (P = 0.08). There was also a significant correlation between % inj.act kg-' in tumour and tumour to blood ratios (P = 0.012) for the 70-120 h group. In the 144-480 h group the correlation was not significant (P = 0.11).
Other factors
The relationship between % inj.act kg-' in tumour and serum CEA levels was not significant in either the early (P = 0.63) or late (P = 0.56) time point group. However, two patients with values in excess of 2,000 tg 1' showed low % inj.act kg-' in tumour (0.608 and 0.,529) and low tumour to blood ratios (0.6 and 1.2). There was no relationship between % inj.act kg-' in tumour and density of CEA in viable tumour in either the early (P = 0.44) or late (P = 0.71) time point group. There was no significant relationship between % inj.act kg-' in tumour and vascularity in viable tumour in either the early (P = 0.39) or late (P = 0.28) time point group. However, in one patient, increased localisation in an ovarian metastasis compared with the primary colonic tumour (12: 1) was associated with an increase in vascularity (4.8:1), in the ovarian vs the colonic tumour. The density of CEA, demonstrated immunohistochemically in the tumour at each site, appeared similar. There was no association between the % inj.act kg-' in tumour and the site (colon or rectum), for the early (P = 0.66) or late (P = 0.14) time point groups. In the 144-480 h group the per cent injected activities were higher in the patients tumours with an infiltrative rather than pushing front (P = 0.02). Time interval between injection and operation (hours) Figure 2 Tumour uptake of 1251 anti-CEA. Relation to time (all patients). n = number of data points. P = correlation coefficient. Line of regression is plotted. Figure 3a shows localisation of autoradiographic grains associated with radiolabelled antibody predominantly in tumour cells, with grains overlying malignant acini. The fibrovascular stroma contains fewer grains. Figure 3b shows normal colonic crypts which contain no grains. Figures 4a and 4b counterstained with antibody to CEA, show the localisation of radiolabelled antibody in cells expressing CEA (4a) and an absence of grains in an area of tumour with low levels of target antigen (4b). However in other areas there are grains associated with malignant glands in which there is only focal positivity for CEA. Figure 5 (counterstained with antibody to vascular endothelium) shows an accumulation of grains in necrotic more than viable areas of tumour. In some tumours there was selective targeting of isolated CEA positive cells in the fibrovascular stroma with adjacent malignant acini virtually unlabelled. Antibody penetration in some areas of tumours was poor. Autoradiography in some areas showed grains on the basement membrane aspect of the tumour, in close proximity to the fibrous stroma. Deeper tumour cells appeared less well targeted (data not shown).
In no sections was there any obvious retention of radiolabelled antibody in vascular endothelium nor associated with the cells or serum protein within blood vessels. This is consistent with clearance of antibody from the circulation at time points corresponding to these patients resections (70 h or more post injection). In some patients accumulations of grains were greatest nearest to blood vessels. However, planar sections give limited three dimensional information about the spatial relationships of blood vessels with glandular structures and tumour cells. Therefore, any conclusions about the access of antibody to tumour cells from the circulation are difficult to make. These autoradiographic results illustrate the extent to which radiolabelled antibody to CEA is distributed heterogeneously in colonic adenocarcinomas. 
Discussion
Correlation of per cent injected activity in tumour with a variety of factors has yielded a number of observations. Whilst no consistent evidence was found that density of antigen expression, tumour vascularisation or moderate elevation of serum CEA influenced tumour localisation, there were some incidental findings. In the two patients with serum CEA values in excess of 2,000 ytg 1' (patients 32 and 33) the % inj.act kg-' in tumour and tumour blood ratios were amongst the lowest recorded. Given that standard man contains 3.1 litres of plasma (MIRD Tables-International Commission on Radiological Protection (October 1974) , Report of the Task Group on Reference Man, Pergamon Press), then 2,000 jig 1' of CEA represents a total of 6.2 mg of CEA antigen. Assuming that intact IgG antibody (molecular weight 150,000) binds serum CEA (molecular weight 200,000) on a one to one basis then at a serum level of 129 pg 1', the concentration of administered antibody (0.4 mg) and antigen would be the same. Clearly not all the antibody can be complexed with antigen since some patients with values of 300 still showed selective uptake in the tumour. But these findings support the hypothesis (Pedley et al., 1989; Martin & Halpern, 1984) that high levels of circulating antigen can affect the potential of antibodies to localise efficiently in tumours.
In one patient (27) when comparing the ovarian metastasis with the primary colonic tumour, there was shown to be an increase in the per cent area occupied by blood vessels (4.8:1) which mirrored a corresponding increase in per cent injected activity (12:1). The absence of any correlation between % inj.act kg-' in tumour and density of CEA in tumour, suggests that penetration into, and/or retention of antibody within malignant glandular structures and on tumour cells, is sub-optimal. This is illustrated by the autoradiographic studies showing that antibody localisation is heterogeneous and not solely related to the presence of antigen.
High levels of circulating antibody predicted high levels of antibody localisation in tumour. However, the considerable variation in tumour to blood ratios (0.31-28.54) suggests that there are other factors which contribute to efficient targeting. Tumour to blood ratios correlated significantly with % inj.act kg-' in the tumour, and inversely with per cent injected activity in the blood, in the 70-120 h time point group. Therefore patients who achieve high tumour to blood ratios do so as both a function of high % inj.act kg-' in tumour and clearance of antibody from the circulation. This suggests that in a proportion of patients at least there is specific antibody targeting. This is supported by data accumulated in our department from patients undergoing radioimmunotherapy with '"'I antibody to CEA (A5B7).
These patients are scanned at serial time points from 3 h post injection and blood samples are collected at corresponding time points. It is possible to quantitate the % inj.act kg-' in both tumour and blood (Begent et al., 1989; Green et al., 1990 ) and tumour to blood ratios can be calculated for each patient over a time course. Patients with high % inj.act kg' in tumour tend to have high tumour to blood ratios.
Whilst the data presented here is from single time points, these observations have implications for antibody directed therapy. Applebaum et al., 1987 and DeNardo et al., 1988 have shown that radiation doses to blood and bone marrow are related. Since myelosuppression is the principal toxicity in radioimmunotherapy, tumour to blood ratio gives an indication of likely therapeutic ratio. The results show that tumour to blood ratios may be improved by rapid clearance of antibody from the circulation. This can be manipulated by giving antibody fragments such as Fab' and Fv which may be cleared more rapidly from the circulation than whole antibody. These smaller molecules may also penetrate more efficiently into tumour giving a further advantage (Sutherland et al., 1987) . Second antibody, directed against the antitumour may also be used to accelerate clearance from the bloodstream (Begent et at., 1989) .
These data also suggest that only patients likely to have high % inj.act kg-'in tumour should be selected for therapy. Autoradiography showed that antibody does not always penetrate efficiency into malignant tumour acini even if they are antigen rich and in some areas only isolated CEA positive cells are labelled. The finding in the 144-480 h group, that there were higher per cent injected activities in the patients tumours with an infiltrative rather than pushing front, suggests that the cellular organisation of malignant glandular structures may influence antibody uptake. This may be due to the basement and basolateral membranes being less well defined in tumours of an infiltrative nature. The diffusion of antibody molecules across membranes and into glandular structures is desirable if they are to reach the luminal surface to be retained where CEA is concentrated in high amounts. Humm and Cobb, 1989 have considered the consequences that heterogeneity of radiolabelled antibody binding has for tumour cell sterilisation. They particularly considered the importance of whether the isotope is extracellular, membrane bound or internalised. They showed that membrane bound antibody has markedly enhanced potential for energy deposition in the nuclei compared with uniform source distribution throughout the tissue.
Lack of penetration into, and poor retention within, many viable tumour areas highlights the need to explore agents with better properties of diffusion or ones which may help to exploit the tumour's own cellular, uptake and transport mechanisms. Better understanding of the reasons for the variation in % inj.act kg-' is needed and it is evident that there are additional parameters to those described in this paper. A knowledge of the extent to which antibody localisation in tumours is either facilitated or impeded is important in order to help design new or modify existing agents for targeted therapy.
